Dr. Steven Chatfield joins Emergent BioSolutions, Inc., as senior v.p.

Steven Chatfield, Ph.D., has been appointed senior vice president of biodefense by Emergent BioSolutions, Inc.

Dr. Chatfield, who most recently served as executive director of the U.K. Health Protection Agency and lead the Agency's Centre for Emergency Preparedness and Response, will play a key role at Emergent in the growth and development of the company's biodefense business.

Prior to his work with the U.K. Health Protection Agency, Dr. Chatfield served from 2005 to 2007 as as Emergent's chief scientific officer as well as the president of Emergent Product Development U.K.

“We are delighted to welcome Dr. Chatfield back to the Emergent team,” Daniel J. Abdun-Nabi, president and chief operating officer at Emergent, said. “A leader of Steve’s stature and caliber, who brings extensive experience from both industry and government, is truly an asset in strengthening Emergent’s core biodefense business not only within the U.S., but also in foreign markets, where we are expanding our presence.”

Dr. Chatfield brings knowledge of global biodefense issues and policies to his new position at Emergent, which will see him serving as an integral part of global initiatives in government affairs, business development, and sales and marketing. He will also be responsible for interacting with various government entities as well as for representing Emergent in scientific, investor and business conferences related to biodefense.

“My career has been devoted to developing and implementing strategies to battle infectious diseases that have global unmet medical needs,” Dr. Chatfield said. "To manage Emergent’s biodefense franchise, which includes BioThrax, the only vaccine licensed by the FDA against anthrax disease, and other product candidates that could potentially protect against deadly pathogens, gives me the opportunity to continue that mission of contributing to safeguarding the health of the world’s population.” 

Dr. Chatfield has more than 27 years experience in the biopharmaceutical industry and has experience in all aspects of research and development. Dr. Chatfield has focused on the development of products to prevent and treat infectious disease and is internationally recognized as an opinion leader in the biotechnology field. Dr. Chatfield has authored more than 100 scientific papers on biotechnology.